Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

GSK now operates in more than 75 countries and has 37 manufacturing ... This vaccine targets 50-year-olds, older adults, and immunocompromised people. Another one of GSK’s vaccines is Arexvy.

And with no admitted fault or failure, I'm delighted that we've also drawn a line under the vast majority of Zantac litigation ... approval by the FDA for all adult patients with primary advanced ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

Although the Zantac settlement resolution announced ... and Prevention refined its RSV vaccine recommendations to adults aged 75 and older as well as those 60 to 74 years old at higher risk ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

Over-the-counter products (Zantac 75 Relief (PL 02855/0081 [GSL]) and Zantac ... which issued a UK-wide drug alert on Tuesday. He added: "GSK is continuing with investigations into the potential ...

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously filed by Valisure. The arrangement is awaiting final approval from the Department of Justice.

So why would GSK, the largest of the four major distributors of the now-recalled stomach acid drug, suddenly abandon the tried-and-true defense mantra, “millions for defense, not a penny for tribute”?

He was initially prescribed ranitidine for the abdominal pain, which did not provide relief. The patient was on no other medications. Clinical examination revealed an afebrile and uncomfortable ...